- Stocks
- Pharma & Healthcare
- Emcure Pharmaceuticals
Emcure Pharmaceuticals share price
NSE: EMCUREPharma & HealthcarePackaging & Containers
Emcure Pharmaceuticals at a glance
Emcure Pharmaceuticals (NSE: EMCURE) closed at ₹1,768.80 on 19 Oct 2026, down 2.92% on the day. With a market capitalisation of ₹33,551 Cr, it ranks 252nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Packaging & Containers.
At its last close the stock traded at 145.9× trailing earnings, against a return on equity of 18.7% in FY26. Over the past year the share price has risen 24.6%. Its 52-week range is ₹1,306.50 (4 Nov 2025) to ₹2,100.70 (18 Sep 2026); the last close is 15.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,580 Cr (+22.8% year on year) and net profit ₹292 Cr (+36.2%), on a consolidated basis. Promoters held 77.83% of the company as of 30 Jun 2026; 0.04% of promoter shares were pledged.
Key numbers
- Market cap
- ₹33,551 CrRank 252 on NSE
- P/E (trailing)
- 145.9×
- Price to book
- 6.11×FY26
- EPS (TTM)
- ₹53.35to Q1 FY27
- ROE
- 18.7%FY26
- ROCE
- 25.7%FY26
- Debt to equity
- 0.24FY26
- Net profit margin
- 14.0%FY26
- Book value / share
- ₹261.09FY26
- 52-week high
- ₹2,100.7018 Sep 2026
- 52-week low
- ₹1,306.504 Nov 2025
- 1-year return
- +24.6%
- RSI (14-day)
- 31.7
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.92% | −5.4% | −7.3% | −5.0% | +24.6% |
Emcure Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,002 Cr | ₹1,963 Cr | ₹2,116 Cr | ₹2,101 Cr | ₹2,270 Cr | ₹2,363 Cr | ₹2,470 Cr | ₹2,580 Cr |
| Revenue YoY | +20.4% | +23.3% | +19.5% | +15.7% | +13.4% | +20.4% | +16.7% | +22.8% |
| Net profit | ₹202 Cr | ₹156 Cr | ₹197 Cr | ₹215 Cr | ₹251 Cr | ₹231 Cr | ₹244 Cr | ₹292 Cr |
| Net profit YoY | +38.2% | +30.3% | +63.0% | +40.8% | +24.7% | +48.2% | +23.6% | +36.2% |
| Net margin | 10.1% | 8.0% | 9.3% | 10.2% | 11.1% | 9.8% | 9.9% | 11.3% |
| EPS | ₹10.33 | ₹8.12 | ₹9.97 | ₹10.92 | ₹12.85 | ₹12.16 | ₹12.84 | ₹15.50 |
Emcure Pharmaceuticals financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹5,855 Cr | ₹5,986 Cr | ₹6,658 Cr | ₹7,896 Cr | ₹9,204 Cr |
| Operating profit | ₹973 Cr | ₹753 Cr | ₹737 Cr | ₹982 Cr | ₹1,318 Cr |
| Net profit | ₹703 Cr | ₹562 Cr | ₹528 Cr | ₹707 Cr | ₹941 Cr |
| EPS (₹) | ₹37.00 | ₹29.00 | ₹28.00 | ₹36.00 | ₹49.00 |
| Cash from operations | ₹768 Cr | ₹747 Cr | ₹1,097 Cr | ₹852 Cr | ₹944 Cr |
| Total debt | ₹717 Cr | ₹744 Cr | ₹767 Cr | ₹190 Cr | ₹252 Cr |
| Shareholders' equity | ₹1,988 Cr | ₹2,501 Cr | ₹2,952 Cr | ₹4,446 Cr | ₹4,950 Cr |
Emcure Pharmaceuticals shareholding pattern
| Holder | 30 Sep 2024 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 78.08% | 77.91% | 77.88% | 77.87% | 77.87% | 77.83% |
| Foreign institutions | 2.91% | 2.86% | 3.29% | 3.59% | 3.35% | 4.88% |
| Domestic institutions | 3.96% | 2.84% | 4.37% | 6.10% | 6.10% | 8.46% |
| Non-institutions | 15.05% | 16.39% | 14.46% | 12.44% | 12.68% | 8.83% |
| Promoter shares pledged | — | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
Emcure Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Emcure Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AJANTPHARMAjanta Pharma | ₹3,296.00 | −0.73% | +35.6% | ₹41,179 Cr | 39.1 | — |
| NHNarayana Hrudayalaya | ₹1,732.90 | +1.34% | −2.3% | ₹35,414 Cr | 43.5 | — |
| EMCUREEmcure Pharmaceuticals | ₹1,768.80 | −2.92% | +24.6% | ₹33,551 Cr | 145.9 | — |
| MEDANTAGlobal Health | ₹1,230.00 | −0.32% | −8.9% | ₹33,071 Cr | 59.6 | — |
| WOCKPHARMAWockhardt | ₹1,904.90 | −2.46% | +34.2% | ₹30,953 Cr | 146 | — |
| LALPATHLABDr. Lal Path Labs | ₹1,830.10 | −1.55% | +18.5% | ₹30,679 Cr | 57.8 | — |
| SAILIFESai Life Sciences | ₹1,391.00 | +0.22% | +62.5% | ₹29,529 Cr | 84.8 | — |
Ask anything about Emcure Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against EMCURE's own history. Try: “Why has EMCURE moved over the last three months?” · “Backtest a 50-day moving-average crossover on EMCURE over five years” · “Compare EMCURE with AJANTPHARM on margins and valuation”
Frequently asked questions about Emcure Pharmaceuticals
What is the share price of Emcure Pharmaceuticals today?
Emcure Pharmaceuticals (NSE: EMCURE) last closed at ₹1,768.80 on 19 Oct 2026. Its 52-week high is ₹2,100.70 and its 52-week low is ₹1,306.50.
What is the market cap of Emcure Pharmaceuticals?
Emcure Pharmaceuticals' market capitalisation is ₹33,551 Cr (₹33,551 Cr) at the 19 Oct 2026 close, ranking 252nd among the NSE companies Pivot tracks.
What is the P/E ratio of Emcure Pharmaceuticals?
Emcure Pharmaceuticals trades at a trailing P/E of 145.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 59.6.
What is the ROE and ROCE of Emcure Pharmaceuticals?
Return on equity was 18.7% in FY26 and return on capital employed was 25.7% in FY26 (consolidated figures).
Is Emcure Pharmaceuticals a debt-free company?
No. Emcure Pharmaceuticals' debt-to-equity ratio was 0.24 in FY26, with total debt of ₹252 Cr.
What were Emcure Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Emcure Pharmaceuticals reported revenue of ₹2,580 Cr, +22.8% year on year, and net profit of ₹292 Cr, +36.2% year on year.
How has Emcure Pharmaceuticals stock performed over the last year?
Emcure Pharmaceuticals' share price has risen 24.6% over the past year, −5.0% over three months and −7.3% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Emcure Pharmaceuticals?
As of 30 Jun 2026: promoters 77.83%, foreign institutions 4.88%, domestic institutions 8.46%, non-institutions 8.83%. 0.04% of promoter shares were pledged.
Who are Emcure Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Emcure Pharmaceuticals by market cap are Ajanta Pharma, Narayana Hrudayalaya, Global Health, Wockhardt, Dr. Lal Path Labs and Sai Life Sciences.
Is Emcure Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Emcure Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EMCURE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text